RECRUITING

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Description

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Conditions

Atopic Dermatitis
Talk to us

Related Conditions:

Atopic Dermatitis

Study Overview

On this page

Study Details

Study overview

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Birmingham

Galderma Investigational Site - 8893, Birmingham, Alabama, United States, 35244

Phoenix

Galdrma Investigational Site - 7077, Phoenix, Arizona, United States, 85006-2754

Phoenix

Galderma Investigational Site 7060, Phoenix, Arizona, United States, 85008-3884

Phoenix

Galderma Investigational Site - 8535, Phoenix, Arizona, United States, 85032-2238

Tucson

Galderma Investigational Site - 7067, Tucson, Arizona, United States, 85718

Corona

Galderma Investigational Site - 7074, Corona, California, United States, 92882

Fountain Valley

Galderma Investigational Site 6836, Fountain Valley, California, United States, 92708-3701

Fremont

Galderma Investigational Site 8224, Fremont, California, United States, 94538-1603

Irvine

Galderma Investigational Site 7100, Irvine, California, United States, 92697

Los Angeles

Galderma Investigational Site 7099, Los Angeles, California, United States, 90024-2801

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
  • * Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
  • * Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
  • * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
  • * Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
  • * Participants who received nemolizumab previously.
  • * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Ages Eligible for Study

12 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Galderma R&D,

Study Record Dates

2027-11-30